GFM
AVDL

GF Fund Management’s Avadel Pharmaceuticals AVDL Stock Holding History

GF Fund Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,089
Closed -$31.9K – 652
2025
Q3 		$31.9K Sell
2,089
-378
-15% -$4.92K ﹤0.01% 436
2025
Q2 		$21.8K Hold
2,467
– – ﹤0.01% 494
2025
Q1 		$19.3K Buy
2,467
+444
+22% +$3.72K ﹤0.01% 506
2024
Q4 		$21.3K Buy
+2,023
New +$24.6K ﹤0.01% 465

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's AVDL Position: Q4 2025 in Review

GF Fund Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 2,089 shares — an estimated $31.9K sold.

GF Fund Management first reported a position in AVDL in Q4 2024 and held it in 4 quarters. The position peaked at $31.9K in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • GF Fund Management reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 2,089 Avadel Pharmaceuticals shares in Q4 2025, an estimated $31.9K.
  • GF Fund Management first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's Avadel Pharmaceuticals position peaked at $31.9K in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.